Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I. Rini, Thomas Powles, Denis Soulières et al.|Nature Medicine|2025Cited by 44
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah Buckley, Naveen Vasudev, Fiona Collinson et al.|BMC Cancer|2019Cited by 17
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)Naveen Vasudev, Thomas Powles, Gemma Ainsworth et al.|Journal of Clinical Oncology|2023Cited by 14
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)Naveen Vasudev, T.B. Powles, Gemma Ainsworth et al.|Annals of Oncology|2021Cited by 9